Heron Fundamentals

HRTX -  USA Stock  

USD 10.20  0.13  1.26%

Heron Therapeutics fundamentals help investors to digest information that contributes to Heron Therapeutics' financial success or failures. It also enables traders to predict the movement of Heron Stock. This fundamental analysis module provides a way for investors to measures Heron Therapeutics' intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Heron Therapeutics stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Heron Fundamentals 

Heron Therapeutics Weighted Average Shares is fairly stable at the moment as compared to the past year. Heron Therapeutics reported Weighted Average Shares of 90.77 Million in 2020. Weighted Average Shares Diluted is likely to rise to about 97.9 M in 2021, whereas Direct Expenses is likely to drop slightly above 30 M in 2021.

Heron Price to Earnings To Growth Analysis

Heron Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
 2018 2019 2020 2021 (projected)
Receivables64.65 M39.88 M41.85 M35.38 M
Inventories39.03 M24.97 M41.91 M45.21 M
PEG Ratio 
PE Ratio 
EPS Growth 
More About Price to Earnings To Growth | All Equity Analysis

Current Heron Therapeutics Price to Earnings To Growth

  (0.10) X  
Most of Heron Therapeutics' fundamental indicators, such as Price to Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Heron Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Compare to competition

Based on the latest financial disclosure, the price to earnings to growth indicator of Heron Therapeutics is roughly -0.1 times. This is 114.08% lower than that of the Healthcare sector and 103.18% lower than that of the Biotechnology industry. The price to earnings to growth for all United States stocks is 102.04% higher than that of the company.

Heron Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Heron Therapeutics's current stock value. Our valuation model uses many indicators to compare Heron Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Heron Therapeutics competition to find correlations between indicators driving Heron Therapeutics's intrinsic value. More Info.
Heron Therapeutics is one of the top stocks in beta category among related companies. It is rated # 2 in price to sales category among related companies fabricating about  9.07  of Price to Sales per Beta. . Price to Sales Ratio is likely to rise to 22.24 in 2021

Heron Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Heron Therapeutics from analyzing Heron Therapeutics' financial statements. These drivers represent accounts that assess Heron Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Heron Therapeutics' important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Net Income Per Employee(1.24 M)(1.36 M)(903.23 K)(886.36 K)(1.02 M)(1.1 M)
Average Assets90.97 M171.11 M406.75 M438.3 M413.81 M446.48 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(169.82 M)(193.06 M)(180.62 M)(208.49 M)(226.16 M)(232.11 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(169.82 M)(193.06 M)(180.62 M)(208.49 M)(226.16 M)(232.11 M)
Earnings before Tax(173.14 M)(197.48 M)(178.84 M)(204.75 M)(227.28 M)(233.26 M)
Average Equity36.79 M85.61 M325.27 M331.61 M300.79 M324.54 M
Enterprise Value520.45 M949.49 M1.97 B2.07 B1.85 B2 B
Free Cash Flow(137.23 M)(172.78 M)(200.95 M)(131.73 M)(191.63 M)(196.68 M)
Invested Capital68.25 M15.24 M342.9 M363.97 M170.53 M141.94 M
Invested Capital Average42.18 M64.27 M244.18 M309.56 M245.35 M264.72 M
Market Capitalization513.36 M986.53 M2.02 B2.12 B1.92 B2.07 B
Tangible Asset Value67.48 M234.31 M462.18 M512.78 M353.56 M291.3 M
Working Capital23.41 M124.89 M355.23 M382.36 M211.69 M185.32 M

Heron Fundamentals

About Heron Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Heron Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heron Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heron Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2021
Deferred Revenue3.2 M3.4 M
Cost of Revenue36.2 M34.1 M
Revenues88.6 M75.3 M
Revenue to Assets 0.25  0.21 
Revenue Per Employee396.4 K313.7 K
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The companys product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL , an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens and CINVANTI, an intravenous formulation of aprepitant, a substance Pneurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management and HTX-034, which is in Phase IbII clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Heron Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pattern Recognition Now


Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Heron Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Heron Therapeutics Piotroski F Score and Heron Therapeutics Altman Z Score analysis. Note that the Heron Therapeutics information on this page should be used as a complementary analysis to other Heron Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fund Screener module to find activelly-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Heron Stock analysis

When running Heron Therapeutics price analysis, check to measure Heron Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeutics is operating at the current time. Most of Heron Therapeutics' value examination focuses on studying past and present price action to predict the probability of Heron Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Heron Therapeutics' price. Additionally, you may evaluate how the addition of Heron Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
The market value of Heron Therapeutics is measured differently than its book value, which is the value of Heron that is recorded on the company's balance sheet. Investors also form their own opinion of Heron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Heron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heron Therapeutics' market value can be influenced by many factors that don't directly affect Heron Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Heron Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.